



**Proteomics International**

LABORATORIES LTD

ASX Release

13 May 2021

ASX code: PIQ

## **Study demonstrates major economic health benefit of PromarkerD - PromarkerD reimbursement update**

- **Independent modelling estimates instigating PromarkerD testing could produce net savings for US payors of US\$862 million over four years per million type 2 diabetes patients tested**
- **The study provides validation of the potential economic health benefit of PromarkerD in diabetic kidney disease management, which improves the likelihood that the test will be reimbursed by payors**
- **Results will be released online ahead of presentation at Virtual ISPOR 2021, the world's leading conference for health economics and outcomes research, from 17-20 May 2021**
- **Proteomics International to seek a CPT Proprietary Laboratory Analyses (PLA) code to facilitate the reimbursement of the innovative PromarkerD test by payors in the US**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to announce the results of an economic health benefit study for PromarkerD following comprehensive economic modelling and consultation with key industry stakeholders. The Company is set to seek a CPT Proprietary Laboratory Analyses (PLA) reimbursement code for its innovative PromarkerD test for diabetic kidney disease.

Independent consultant Boston Healthcare Associates modelled the budget impact of a proactive testing regime using PromarkerD for assessing diabetic kidney disease in patients with type 2 diabetes, compared to the current standard of care. The study found that, at US\$150 a test, and over four years, PromarkerD produced estimated savings of up to US\$2.4 billion against costs of US\$1.5 billion for every million type 2 diabetes patients tested.

The modelling showed instigating PromarkerD testing produced estimated net savings for payors of US\$862 million over four years per million patients tested. The savings primarily arise from slowing the progression of diabetic kidney disease against costs from increased testing and the use of preventative medications.

Proteomics International managing director Dr Richard Lipscombe said, *"With PromarkerD testing, patients may delay or avoid costly end outcomes such as dialysis and kidney transplants. Given there are approximately 31 million diabetics in the United States alone, the economic benefit of PromarkerD is clearly evident."*

Boston Healthcare Associates and Proteomics International will present the modelling at the annual conference of the Professional Society for Health Economics and Outcomes Research, Virtual ISPOR 2021, the world's leading conference for health economics, from 17-20 May 2021. The event is typically attended by global healthcare leaders, including policy makers, payors and health economists.

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Proteomics International will now pursue a reimbursement code for PromarkerD based on its extensive engagement with expert panels representing physicians, laboratories and payors, including national and regional entities. Securing a reimbursement code will facilitate the reimbursement of the PromarkerD test by insurance companies and other payors in the US.

A CPT Proprietary Laboratory Analyses (PLA) code uniquely identifies a test for the laboratory and the payors. Reimbursement codes and payer coverage in the US are initiated through the American Medical Association (AMA) and its Current Procedural Terminology (CPT) Editorial Panel. The approval and acceptance of a PLA code follows assessment of the economic health benefit and clinical utility of a new test.

Dr Lipscombe said although securing a code is relatively straightforward, it is imperative that the code is covered and reimbursed by insurers. *"Our surveys indicate that a price between US\$100 and US\$300 per test would be considered reasonable, while US\$550 or higher would be considered prohibitively expensive. The Company looks forward to updating shareholders when the final details have been determined for the reimbursement code."*

Authorised by the Board of Proteomics International Laboratories Ltd (ASX:PIQ).

ENDS

#### **About PromarkerD ([www.PromarkerD.com](http://www.PromarkerD.com))**

PromarkerD is a predictive test for the early detection of chronic kidney disease (CKD) in patients with type-2 diabetes. CKD is one of the major complications arising from diabetes and if unchecked can lead to dialysis or kidney transplant.

The patented PromarkerD test system uses a simple blood test to detect a unique 'fingerprint' of the early onset of disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR)).

In clinical studies published in leading journals PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. The PromarkerD immunoassay, the PromarkerD mass spectrometry assay, and the PromarkerD software hub have each achieved CE Mark registration in the European Union.

Further information is available through the PromarkerD web portal.

To visit the PromarkerD virtual booth please see: [www.PromarkerD.com/product](http://www.PromarkerD.com/product)

#### **About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth's QEII Medical Campus.

Proteomics International's business model is centred on the commercialisation of the Company's world-leading test for diabetic kidney disease, PromarkerD. The Company offsets the cash burn from R&D and product development through provision of specialist analytical services, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests.

#### **For further information please contact:**

Dr Richard Lipscombe  
Managing Director

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
Corporate Advisor & Investor Relations  
Candour Advisory  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

Kyle Moss  
Corporate Advisor  
Euroz Hartleys  
T: +61 8 9488 1400  
E: [kmoss@euroz.com](mailto:kmoss@euroz.com)